Trial Outcomes & Findings for An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis (NCT NCT00454584)

Last Updated: 2012-11-21

Results Overview

Number of participants achieving greater than or equal to 75 percentage improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12. PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst). Baseline visit refers to Week 0.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

903 participants

Primary outcome timeframe

Baseline and Week 12

Results posted on

2012-11-21

Participant Flow

903 partcipants received either ustekinumab (CNTO 1275) or etanercept at 67 sites in North America and Europe.

Participant milestones

Participant milestones
Measure	Etanercept (CP) Controlled period (Week 0-12) - Etanercept group	Ustekinumab 45 mg (CP) Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) Controlled period (Week 0-12) - Ustekinumab 90 mg group	Etanercept (After CP) After Controlled period (Week 12- 64) - receiving etanercept at Weeks 0 -\> receiving ustekinumab 90 mg if becoming a nonresponder during Week 12 and Week 40	Ustekinumab 45 mg (After CP) After Controlled period (Week 12-64) - receiving ustekinumab 45 mg at Weeks 0 -\> retreated with ustekinumab 45 mg if becoming a nonresponder during Week 12 and Week 40.	Ustekinumab 90 mg (After CP) After Controlled period (Week 12-64) - receiving ustekinumab 90 mg at Weeks 0 -\> retreated with ustekinumab 90 mg if becoming a nonresponder during Week 12 and Week 40.
Controlled Period STARTED	347	209	347	0	0	0
Controlled Period COMPLETED	336	201	342	0	0	0
Controlled Period NOT COMPLETED	11	8	5	0	0	0
After Controlled Period STARTED	0	0	0	336	201	342
After Controlled Period COMPLETED	0	0	0	310	189	310
After Controlled Period NOT COMPLETED	0	0	0	26	12	32

Reasons for withdrawal

Reasons for withdrawal
Measure	Etanercept (CP) Controlled period (Week 0-12) - Etanercept group	Ustekinumab 45 mg (CP) Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) Controlled period (Week 0-12) - Ustekinumab 90 mg group	Etanercept (After CP) After Controlled period (Week 12- 64) - receiving etanercept at Weeks 0 -\> receiving ustekinumab 90 mg if becoming a nonresponder during Week 12 and Week 40	Ustekinumab 45 mg (After CP) After Controlled period (Week 12-64) - receiving ustekinumab 45 mg at Weeks 0 -\> retreated with ustekinumab 45 mg if becoming a nonresponder during Week 12 and Week 40.	Ustekinumab 90 mg (After CP) After Controlled period (Week 12-64) - receiving ustekinumab 90 mg at Weeks 0 -\> retreated with ustekinumab 90 mg if becoming a nonresponder during Week 12 and Week 40.
Controlled Period Adverse Event	5	2	1	0	0	0
Controlled Period Lost to Follow-up	1	2	2	0	0	0
Controlled Period Other	5	4	2	0	0	0
After Controlled Period Adverse Event	0	0	0	9	3	9
After Controlled Period Lack of Efficacy	0	0	0	1	0	0
After Controlled Period Lost to Follow-up	0	0	0	2	4	6
After Controlled Period Other	0	0	0	13	5	17

Baseline Characteristics

An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Group I: Etanercept n=347 Participants Participants received Etanercept 50 mg twice weekly through Week 12. Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16 and 20. Participants with PGA leeser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.	Group II: Ustekinumab 45 mg n=209 Participants Participants received ustekinumab 45 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 45 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 45 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.	Group III: Ustekinumab 90 mg n=347 Participants Participants received ustekinumab 90 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.	Total n=903 Participants Total of all reporting groups
Age Continuous	45.7 years STANDARD_DEVIATION 13.40 • n=5 Participants	45.1 years STANDARD_DEVIATION 12.56 • n=7 Participants	44.8 years STANDARD_DEVIATION 12.29 • n=5 Participants	45.2 years STANDARD_DEVIATION 12.78 • n=4 Participants
Sex: Female, Male Female	101 Participants n=5 Participants	76 Participants n=7 Participants	113 Participants n=5 Participants	290 Participants n=4 Participants
Sex: Female, Male Male	246 Participants n=5 Participants	133 Participants n=7 Participants	234 Participants n=5 Participants	613 Participants n=4 Participants

PRIMARY outcome

Timeframe: Baseline and Week 12

Population: Intent to treat. All participants randomized were included in the analysis according to the assigned treatment groups. Participants is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or has missing data at Week 12.

Outcome measures

Outcome measures
Measure	Group I: Etanercept n=347 Participants Participants received Etanercept 50 mg twice weekly through Week 12. Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16 and 20. Participants with PGA leeser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.	Group II: Ustekinumab 45 mg n=209 Participants Participants received ustekinumab 45 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 45 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 45 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.	Group III: Ustekinumab 90 mg n=347 Participants Participants received ustekinumab 90 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.
Number of Participants Achieving a Greater Than or Equal to 75 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 12	197 Participants	141 Participants	256 Participants

SECONDARY outcome

Timeframe: Week 12

Population: Intent to treat. All randomly assigned participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or had a missing PGA score.

Number of participants achieving a physician global assessment (PGA) (0-5) of cleared or minimal at Week 12. The PGA is 7-point scale used in clinical trial of various diseases. In this the physician checks the state of the disease and gives them score from 0 (clear) to 5 (severe).

Outcome measures

Outcome measures
Measure	Group I: Etanercept n=347 Participants Participants received Etanercept 50 mg twice weekly through Week 12. Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16 and 20. Participants with PGA leeser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.	Group II: Ustekinumab 45 mg n=209 Participants Participants received ustekinumab 45 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 45 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 45 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.	Group III: Ustekinumab 90 mg n=347 Participants Participants received ustekinumab 90 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.
Number of Participants With Physician's Global Assessment (PGA) of Cleared or Minimal at Week 12	170 Participants	136 Participants	245 Participants

SECONDARY outcome

Timeframe: Baseline and Week 12

Population: Intent to treat. All randomly assigned participants were included in the analysis according to the assigned treatment groups. A participant is considered a non-responder if the participant has used any pre-specified prohibited medications, discontinued due to lack of efficacy, or had a missing Week 12 PASI score.

Number of participants achieving greater than or equal to 90 percentage improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12. PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst).

Outcome measures

Outcome measures
Measure	Group I: Etanercept n=347 Participants Participants received Etanercept 50 mg twice weekly through Week 12. Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16 and 20. Participants with PGA leeser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.	Group II: Ustekinumab 45 mg n=209 Participants Participants received ustekinumab 45 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 45 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 45 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.	Group III: Ustekinumab 90 mg n=347 Participants Participants received ustekinumab 90 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.
Number of Participants Achieving a Greater Than or Equal to 90 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 90) Score at Week 12	80 Participants	76 Participants	155 Participants

SECONDARY outcome

Timeframe: Up to Week 52. Retreatment may occur anytime between Week 16 and Week 40 depending on time of losing PGA response. Hence end of 12 weeks of retreatment would be between Week 28 and Week 52, inclusive.

Population: Participants who were randomized to ustekinumab, had a PGA score less than or equal to 2 at Week 12, and were retreated upon losing PGA response (PGA greater than or equal to 3).

The difference between the PASI score at Week 12 and that achieved after 12 weeks of retreatment. The PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst).

Outcome measures

Outcome measures
Measure	Group I: Etanercept n=152 Participants Participants received Etanercept 50 mg twice weekly through Week 12. Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16 and 20. Participants with PGA leeser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.	Group II: Ustekinumab 45 mg n=240 Participants Participants received ustekinumab 45 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 45 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 45 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.	Group III: Ustekinumab 90 mg Participants received ustekinumab 90 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.
Difference in Psoriasis Area Severity Index Between Week 12 and That Achieved 12 Weeks After Retreatment (Week R12)	-0.99 Score on a scale Standard Error 3.799	-0.30 Score on a scale Standard Error 4.124	—

Adverse Events

Etanercept (CP)

Serious events: 4 serious events

Other events: 154 other events

Deaths: 0 deaths

Ustekinumab 45 mg (CP)

Serious events: 4 serious events

Other events: 85 other events

Deaths: 0 deaths

Ustekinumab 90 mg (CP)

Serious events: 4 serious events

Other events: 126 other events

Deaths: 0 deaths

Etanercept (After CP)

Serious events: 8 serious events

Other events: 60 other events

Deaths: 0 deaths

Etanercept -> Ustekinumab 90 mg (After CP)

Serious events: 10 serious events

Other events: 102 other events

Deaths: 0 deaths

Ustekinumab 45 mg (After CP)

Serious events: 13 serious events

Other events: 85 other events

Deaths: 0 deaths

Ustekinumab 90 mg (After CP)

Serious events: 22 serious events

Other events: 164 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Etanercept (CP) n=347 participants at risk Controlled period (Week 0-12) - Etanercept group	Ustekinumab 45 mg (CP) n=209 participants at risk Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) n=347 participants at risk Controlled period (Week 0-12) - Ustekinumab 90 mg group	Etanercept (After CP) n=337 participants at risk After Controlled period (Week 12-64) - receiving etanercept at Weeks 0 -\> prior to being treated with ustekinumab	Etanercept -> Ustekinumab 90 mg (After CP) n=295 participants at risk After Controlled period (Week 12-64) - receiving etanercept at Weeks 0 -\> receiving ustekinumab 90 mg upon becoming a nonresponder during Week 12 and Week 40. This group is a subpopulation of Etanercept (after CP).	Ustekinumab 45 mg (After CP) n=204 participants at risk After Controlled period (Week 12-64) - receiving ustekinumab 45 mg at Weeks 0 -\> retreated with ustekinumab 45 mg if becoming a nonresponder during Week 12 and Week 40.	Ustekinumab 90 mg (After CP) n=343 participants at risk After Controlled period (Week 12-64) - receiving ustekinumab 90 mg at Weeks 0 -\> retreated with ustekinumab 90 mg if becoming a nonresponder during Week 12 and Week 40.
Blood and lymphatic system disorders Anaemia	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Angina pectoris	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Atrial fibrillation	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Cardiac failure congestive	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Myocardial infarction	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Cardiac disorders Supraventricular tachycardia	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.30% 1/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Endocrine disorders Hyperthyroidism	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Eye disorders Diplopia	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Eye disorders Eye pain	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Abdominal pain upper	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Diverticulitis intestinal haemorrhagic	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Enterocolitis	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Gastritis	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Ileus	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Inflammatory bowel disease	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.30% 1/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Mallory-Weiss syndrome	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Nausea	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Pancreatitis	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.48% 1/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.30% 1/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Peptic ulcer haemorrhage	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Uvulitis	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Gastrointestinal disorders Vomiting	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Asthenia	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Chest discomfort	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.30% 1/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Chest pain	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.48% 1/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Cyst	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Multi-organ failure	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Pain	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Pyrexia	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Hepatobiliary disorders Hepatic steatosis	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Immune system disorders Sarcoidosis	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.30% 1/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Appendicitis	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Gastrointestinal infection	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations HIV infection	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Haematoma infection	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Meningitis bacterial	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Pneumonia	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.58% 2/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Pneumonia staphylococcal	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Rash pustular	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Respiratory tract infection viral	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Sepsis	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.58% 2/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Subcutaneous abscess	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Urosepsis	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Foreign body trauma	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Gun shot wound	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Hip fracture	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.30% 1/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Lower limb fracture	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Meniscus lesion	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.30% 1/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Overdose	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.30% 1/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Road traffic accident	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Metabolism and nutrition disorders Dehydration	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Metabolism and nutrition disorders Diabetes mellitus	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Metabolism and nutrition disorders Hyperlipidaemia	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Spinal column stenosis	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.68% 2/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Systemic lupus erythematosus	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.48% 1/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Chronic lymphocytic leukaemia	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon adenoma	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Mycosis fungoides	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oral neoplasm	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Dizziness	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Hypoaesthesia	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Motor dysfunction	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Pregnancy, puerperium and perinatal conditions Abortion spontaneous	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Psychotic disorder	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.48% 1/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Psychiatric disorders Substance abuse	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Renal and urinary disorders Nephrolithiasis	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Renal and urinary disorders Renal failure	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Renal and urinary disorders Renal failure acute	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Reproductive system and breast disorders Breast mass	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Surgical and medical procedures Finger amputation	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Femoral artery occlusion	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.30% 1/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Hypertension	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.48% 1/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.58% 2/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Ischaemia	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.49% 1/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Vascular disorders Microangiopathy	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.

Other adverse events

Other adverse events
Measure	Etanercept (CP) n=347 participants at risk Controlled period (Week 0-12) - Etanercept group	Ustekinumab 45 mg (CP) n=209 participants at risk Controlled period (Week 0-12) - Ustekinumab 45 mg group	Ustekinumab 90 mg (CP) n=347 participants at risk Controlled period (Week 0-12) - Ustekinumab 90 mg group	Etanercept (After CP) n=337 participants at risk After Controlled period (Week 12-64) - receiving etanercept at Weeks 0 -\> prior to being treated with ustekinumab	Etanercept -> Ustekinumab 90 mg (After CP) n=295 participants at risk After Controlled period (Week 12-64) - receiving etanercept at Weeks 0 -\> receiving ustekinumab 90 mg upon becoming a nonresponder during Week 12 and Week 40. This group is a subpopulation of Etanercept (after CP).	Ustekinumab 45 mg (After CP) n=204 participants at risk After Controlled period (Week 12-64) - receiving ustekinumab 45 mg at Weeks 0 -\> retreated with ustekinumab 45 mg if becoming a nonresponder during Week 12 and Week 40.	Ustekinumab 90 mg (After CP) n=343 participants at risk After Controlled period (Week 12-64) - receiving ustekinumab 90 mg at Weeks 0 -\> retreated with ustekinumab 90 mg if becoming a nonresponder during Week 12 and Week 40.
General disorders Fatigue	3.7% 13/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	3.8% 8/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	5.5% 19/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.34% 1/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	2.5% 5/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	2.0% 7/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Injection site erythema	15.3% 53/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.96% 2/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.86% 3/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.68% 2/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 5/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Injection site haematoma	7.2% 25/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.48% 1/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.7% 6/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.58% 2/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
General disorders Injection site swelling	7.2% 25/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.4% 3/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.00% 0/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.29% 1/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Influenza	1.4% 5/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.48% 1/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.2% 4/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 5/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	5.1% 15/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	4.9% 10/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	4.7% 16/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Nasopharyngitis	8.6% 30/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	10.0% 21/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	9.8% 34/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	7.4% 25/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	12.9% 38/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	16.7% 34/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	18.4% 63/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Infections and infestations Upper respiratory tract infection	5.8% 20/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	6.2% 13/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	6.3% 22/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	6.5% 22/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	11.9% 35/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	14.2% 29/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	16.0% 55/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Arthralgia	2.3% 8/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	5.3% 11/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	2.9% 10/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.2% 4/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	2.4% 7/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	3.9% 8/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	4.7% 16/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Musculoskeletal and connective tissue disorders Back pain	2.0% 7/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	6.7% 14/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	4.3% 15/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.89% 3/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.0% 3/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	2.5% 5/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	6.4% 22/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Nervous system disorders Headache	11.0% 38/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	14.8% 31/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	12.1% 42/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 5/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	3.1% 9/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	3.9% 8/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	6.1% 21/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	4.0% 14/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	2.4% 5/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	4.0% 14/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	0.59% 2/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.0% 3/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	5.4% 11/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.7% 6/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.
Skin and subcutaneous tissue disorders Pruritus	4.0% 14/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	5.7% 12/209 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	4.6% 16/347 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 5/337 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	2.0% 6/295 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.5% 3/204 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.	1.7% 6/343 • Week 64 One participant in Etanercept (after controlled period \[CP\]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.

Additional Information

Senior Director, Compound Development Team Leader

Centocor Research & Development, Inc.

Phone: 1 215-793-7612

Results disclosure agreements

Principal investigator is a sponsor employee Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
Publication restrictions are in place

Restriction type: OTHER